management of hereditary angioedema in the uk a comparison with international guidelines

Original title: “Management of hereditary angioedema in the UK: a comparison with international guidelines.”

hereditary angioedema in women hormonal and reproductive influences on disease activity

Original title: “Hereditary angioedema in women: Hormonal and reproductive influences on disease activity.”

determining the clinical impact of attack triggers in patients with hereditary angioedema

Original title: “Determining the clinical impact of attack triggers in patients with hereditary angioedema.”

evaluating deucrictibant for the treatment of hereditary angioedema

Original title: “Evaluating deucrictibant for the treatment of hereditary angioedema.”

real world safety and effectiveness of icatibant in patients with hereditary angioedema hae post marketing surveillance in japan

Original title: “Real-World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (HAE): Post-Marketing Surveillance in Japan.”

lanadelumab use for hereditary angioedema long term prophylaxis over the last 7 years a narrative review of clinical and real world data

Original title: “Lanadelumab Use for Hereditary Angioedema Long-Term Prophylaxis Over the Last 7 Years: A Narrative Review of Clinical and Real-World Data.”

rare case of hereditary angioedema in a 7 year old girl presentation diagnosis and bridging the management gap

Original title: “A Rare Case of Hereditary Angioedema in a 7-Year-Old Girl: Presentation, Diagnosis, and Bridging the Management Gap.”

berotralstat during pregnancy in a patient with hereditary angioedema

Original title: “Berotralstat During Pregnancy in a Patient With Hereditary Angioedema.”

social determinants of health in newly diagnosed hereditary angioedema and their impact on healthcare resource utilization outcomes

Original title: “Social Determinants of Health in Newly Diagnosed Hereditary Angioedema and Their Impact on Healthcare Resource Utilization Outcomes.”

lanadelumab in hereditary angioedema extending dose intervals from every 2 weeks to every 4 weeks

Original title: “Lanadelumab in Hereditary Angioedema: Extending Dose Intervals from Every 2 Weeks to Every 4 Weeks.”

complexity analysis of heart rate variability application to holter monitoring in patients with hereditary angioedema due to c1 inhibitor deficiency

Original title: “Complexity analysis of heart rate variability: application to Holter monitoring in patients with hereditary angioedema due to C1 inhibitor deficiency.”

case report hereditary angioedema accompanied by chronic spontaneous urticaria

Original title: “Case Report: Hereditary Angioedema Accompanied by Chronic Spontaneous Urticaria.”

donidalorsen for hereditary angioedema long term results from a 4 year phase 2 open label extension study

Original title: “Donidalorsen for hereditary angioedema: Long-term results from a 4-year phase 2 open-label extension study.”

international delphi study on barriers to on demand treatment of hereditary angioedema attacks

Original title: “An International Delphi Study on Barriers to On-Demand Treatment of Hereditary Angioedema Attacks.”

rethinking the management of hereditary angioedema

Original title: “Rethinking the management of hereditary angioedema.”

burden of hereditary angioedema results from a multinational survey of caregivers for adult and pediatric patients

Original title: “Burden of hereditary angioedema: results from a multinational survey of caregivers for adult and pediatric patients.”

<strong>BioCryst is acquiring Astria Therapeutics</strong> in a cash-and-stock deal that gives the company a long-acting preventive therapy for the rare disease hereditary angioedema. By Ned Pagliarulo, Jacob Bell and Julia Himmel • Updated Oct.

Original title: “As biotech recovers, venture firms’ preferences appear to shift | BioPharma Dive”

patient experience of hereditary angioedema findings from a racially diverse sample of adult patients

Original title: “The patient experience of hereditary angioedema: findings from a racially diverse sample of adult patients.”

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue. But, while Intellia’s clinical progress has at times displayed CRISPR’s massive therapeutic potential, the company has burned through more than $2 billion since inception and twice laid off staff amid shifting research plans. Its share price sits near record lows, too, following the death of a study participant and suspension of one of its top programs. Intellia still has a shot at success, though. In the first half of 2026, it’s expecting results from a Phase 3 trial testing a possible treatment for a rare condition called hereditary angioedema. Clinical trial results have fueled many of these outcomes, spurring interest from acquirers or investors. This year, other important readouts lay ahead in obesity, infectious diseases, rare disorders and more. Miller, of Evercore, projects sales would top out at $500 million annually in peak years, given the way gene therapy launches have gone so far. — Ben Fidler ... Vertex Pharmaceuticals is best known for a cystic fibrosis drug business that now regularly brings in more than $10 billion each year. But pressure to recreate that success elsewhere is intensifying, as a pain medicine it recently brought to market may not be the blockbuster it once hoped. One drug Vertex is developing for a rare kidney disease could be part of the solution. The second is in people with obesity and diabetes, while the third is in those with obesity and established cardiovascular disease, as defined by a previous heart attack or stroke. Combined, the trials have enrolled more than 5,000 people. Success in these studies would keep Lilly ahead of a raft of emerging competitors — among them chief rival Novo Nordisk, which is currently trying to win approval of a dual-acting therapy.

Original title: “10 clinical trials to watch in the first half of 2026 | BioPharma Dive”